Mereo Stock Future Price Prediction


USD 1.35  0.20  17.39%   

Mereo Biopharma Group stock price prediction is an act of determining the future value of Mereo Biopharma shares using few different conventional methods such as EPS estimation, analyst consensus, or fundamental intrinsic valuation. The successful prediction of Mereo Biopharma's future price could yield a significant profit. Please, note that this module is not intended to be used solely to calculate an intrinsic value of Mereo Biopharma and does not consider all of the tangible or intangible factors available from Mereo Biopharma's fundamental data. We analyze noise-free headlines and recent hype associated with Mereo Biopharma Group, which may create opportunities for some arbitrage if properly timed.
Additionally, see Mereo Biopharma Basic Forecasting Models to cross-verify your projections.
It is a matter of debate whether stock price prediction based on information in financial news can generate a strong buy or sell signal. We use our internally-built news screening methodology to estimate the value of Mereo Biopharma based on different types of headlines from major news networks to social media. The Mereo stock price prediction module provides an analysis of price elasticity to changes in media outlook on Mereo Biopharma over a specific investment horizon.
Wall Street Target Price
Using Mereo Biopharma hype-based prediction, you can estimate the value of Mereo Biopharma Group from the perspective of Mereo Biopharma response to recently generated media hype and the effects of current headlines on its competitors. We also analyze overall investor sentiment towards Mereo Biopharma using Mereo Biopharma's stock options and short interest. It helps to benchmark the overall future attitude of investors towards Mereo using crowd psychology based on the activity and movement of Mereo Biopharma's stock price.
Mereo Biopharma Return on Invested Capital is quite stable at the moment as compared to the past year. The company's current value of Return on Invested Capital is estimated at 1.36. Tangible Assets Book Value per Share is expected to rise to 1.07 this year, although the value of Current Ratio will most likely fall to 6.98.

Mereo Biopharma Short Interest

A significant increase or decrease in Mereo Biopharma's short interest from the previous month could be a good indicator of investor sentiment towards Mereo. Short interest can provide insight into the potential direction of Mereo Biopharma stock and how bullish or bearish investors feel about the market overall. An investor who is long Mereo Biopharma may also wish to track short interest. As short interest increases, investors should be becoming more worried about Mereo Biopharma and may potentially protect profits, hedge Mereo Biopharma with its derivative instruments, or be ready for some potential downside.
200 Day MA
Short Percent
Short Ratio
Shares Short Prior Month
5.2 M
50 Day MA
Shares Short
4.8 M

Mereo Biopharma Group Hype to Price Pattern

Investor biases related to Mereo Biopharma's public news can be used to forecast risks associated with investment in Mereo. The trend in average sentiment can be used to explain how an investor holding Mereo can time the market purely based on public headlines and social activities around Mereo Biopharma Group. Please note that most equiteis that are difficult to arbitrage are affected by market sentiment the most.
Some investors profit by finding stocks that are overvalued or undervalued based on market sentiment. The correlation of Mereo Biopharma's market sentiment to its price can help taders to make decisions based on the overall investors consensus about Mereo Biopharma.

Mereo Biopharma Implied Volatility

Mereo Biopharma's implied volatility exposes the market's sentiment of Mereo Biopharma Group stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Mereo Biopharma's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Mereo Biopharma stock will not fluctuate a lot when Mereo Biopharma's options are near their expiration.
This module is based on analyzing investor sentiment around taking a position in Mereo Biopharma. This speculative approach is based exclusively on the idea that markets are driven by emotions such as investor fear and greed. The fear of missing out, i.e., FOMO, can cause potential investors in Mereo Biopharma to buy its stock at a price that has no basis in reality. In that case, they are not buying Mereo because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.

Mereo Biopharma after-hype prediction price

  $ 1.8  
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Mereo Biopharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Mereo Biopharma in the context of predictive analytics.
LowReal ValueHigh
1 Analysts
LowTarget PriceHigh
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Mereo Biopharma. Your research has to be compared to or analyzed against Mereo Biopharma's peers to derive any actionable benefits. When done correctly, Mereo Biopharma's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Mereo Biopharma Group.

Mereo Biopharma After-Hype Price Prediction Density Analysis

As far as predicting the price of Mereo Biopharma at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Mereo Biopharma or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many smart people who confused the symmetrical distributions of stock prices, such as prices of Mereo Biopharma, with the unreliable approximations that try to describe financial returns.
   Next price density   
       Expected price to next headline  

Mereo Biopharma Estimiated After-Hype Price Volatility

In the context of predicting Mereo Biopharma's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Mereo Biopharma's historical news coverage. Mereo Biopharma's after-hype downside and upside margins for the prediction period are 0.09 and 13.35, respectively. We have considered Mereo Biopharma's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value 1.35
After-hype Price
Mereo Biopharma is dangerous asset. Analysis and calculation of next after-hype price of Mereo Biopharma Group is based on 3 months time horizon.

Mereo Biopharma Stock Price Prediction Analysis

Have you ever been surprised when a price of a company such as Mereo Biopharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Mereo Biopharma backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Mereo Biopharma, there might be something going there, and it might present an excellent short sale opportunity.
Expected ReturnPeriod VolatilityHype ElasticityRelated ElasticityNews DensityRelated DensityExpected Hype
 2.35  11.55  0.45    5.45  5 Events / Month0 Events / MonthIn about 5 days
Latest traded priceExpected after-news pricePotential return on next major newsAverage after-hype volatility

Mereo Biopharma Hype Timeline

Mereo Biopharma Group is now traded for 1.35. The entity has historical hype elasticity of 0.45 and average elasticity to hype of competition of -5.45. Mereo is forecasted to increase in value after the next headline with price projected to jump to 1.8 or above. The average volatility of media hype impact on the company stock price is over 100%. The price upswing on the next news is forecasted to be 33.33% whereas the daily expected return is now at 2.35%. The volatility of related hype on Mereo Biopharma is about 497.84% with expected price after next announcement by competition of -4.1. The company currently holds 16.76 M in liabilities with Debt to Equity (D/E) ratio of 0.19, which may suggest the company is not taking enough advantage from borrowing. Mereo Biopharma Group has a current ratio of 7.76, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Mereo Biopharma until it has trouble settling it off, either with new capital or with free cash flow. So, Mereo Biopharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Mereo Biopharma Group sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Mereo to invest in growth at high rates of return. When we think about Mereo Biopharma's use of debt, we should always consider it together with cash and equity.Given the investment horizon of 90 days the next forecastedpress releasewill be in about 5 days.
Additionally, see Mereo Biopharma Basic Forecasting Models to cross-verify your projections.

Mereo Biopharma Related Hype Analysis

Having access to credible news sources related to Mereo Biopharma's direct competition is more important than ever and may enhance your ability to predict Mereo Biopharma's future price movements. Getting to know how Mereo Biopharma rivals react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Mereo Biopharma may potentially react to the hype associated with one of its peers.
At Risk
GOOGLAlphabet Cl A(2.32) 10 per month 2.22  0.0173  4.20 (3.92)  10.75 

Mereo Biopharma Additional Predictive Modules

Most predictive techniques to examine Mereo price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Mereo using various technical indicators. When you analyze Mereo charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.

About Mereo Biopharma Predictive Indicators

The successful prediction of Mereo Biopharma stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Mereo Biopharma Group, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Mereo Biopharma based on analysis of Mereo Biopharma hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Mereo Biopharma's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Mereo Biopharma's related companies.
 2010 2021 (projected)

Story Coverage note for Mereo Biopharma

The number of cover stories for Mereo Biopharma depends on current market conditions and Mereo Biopharma's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Mereo Biopharma is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Mereo Biopharma's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.

Mereo Biopharma Short Properties

Mereo Biopharma's future price predictability will typically decrease when Mereo Biopharma's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Mereo Biopharma Group often depends not only on the future outlook of the potential Mereo Biopharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Mereo Biopharma's indicators that are reflective of the short sentiment are summarized in the table below.
Shares Percent Shares Out4.45%
Float Shares50.03M
Shares Short Prior Month3.56M
Average Daily Volume Last 10 Day1.39M
Average Daily Volume In Three Month5.3M
Date Short Interest15th of July 2022
Additionally, see Mereo Biopharma Basic Forecasting Models to cross-verify your projections. Note that the Mereo Biopharma Group information on this page should be used as a complementary analysis to other Mereo Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.

Complementary Tools for Mereo Stock analysis

When running Mereo Biopharma Group price analysis, check to measure Mereo Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mereo Biopharma is operating at the current time. Most of Mereo Biopharma's value examination focuses on studying past and present price action to predict the probability of Mereo Biopharma's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Mereo Biopharma's price. Additionally, you may evaluate how the addition of Mereo Biopharma to your portfolios can decrease your overall portfolio volatility.
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Global Correlations
Find global opportunities by holding instruments from different markets
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Is Mereo Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mereo Biopharma. If investors know Mereo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mereo Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
134.5 M
Return On Assets
Return On Equity
The market value of Mereo Biopharma Group is measured differently than its book value, which is the value of Mereo that is recorded on the company's balance sheet. Investors also form their own opinion of Mereo Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Mereo Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mereo Biopharma's market value can be influenced by many factors that don't directly affect Mereo Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mereo Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine Mereo Biopharma value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mereo Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.